NCT06187610

Brief Summary

The increasing shift from face-to-face to online patient-clinician encounters in the healthcare system requires patients to be more involved in their medical care. This raises the urgent need to evaluate the extent to which proactive patients' self-care can be supported, particularly by informed telemedicine digital channels. Despite this imperative, research offering evidence-based instructional design of digital education remains surprisingly scarce. Embracing the framework of science education, which highlights the functional role of different knowledge types in educational processes, the current study seeks to evaluate an educational approach aimed at supporting cancer patients undergoing chemotherapy. Cancer treatment serves as an exemplar health condition, demanding daily self-management from patients. The objectives of our research are as follows: (1) To delineate the types of knowledge required for effective symptom management, active participation in one's healthcare, and judicious decision-making regarding emergency room (ER) visits, with a focus on mechanistic knowledge pertaining to the rationale for treatment and procedural knowledge concerning the treatment regimen. (2) To appraise the impact of a digital learning environment in contrast to traditional methods on patients' acquisition of mechanistic and procedural knowledge. (3) To identify how patients engage with the digital patient education environment aiming to outline leaning patterns. The investigators hypothesize that implementing digital education will enhance patients' understanding of both the 'why' (mechanistic) and 'how' (procedural) aspects of their treatment. Importantly, the investigators expect that mechanistic knowledge will be more impactful than procedural knowledge, leading to better symptom management and patient involvement, and ultimately reducing unnecessary visits to the ER.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
110

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2022

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

December 17, 2023

Completed
16 days until next milestone

First Posted

Study publicly available on registry

January 2, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2024

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2024

Completed
Last Updated

January 3, 2024

Status Verified

December 1, 2023

Enrollment Period

1.7 years

First QC Date

December 17, 2023

Last Update Submit

December 31, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Symptom self-management knowledge

    Measured by performance accuracy in a cancer-specific knowledge test

    The test will be conducted in two time-points of the study, Time 0 (pre) and Time 2 (after two months)

Secondary Outcomes (3)

  • Self-efficacy in symptom management

    The questionnaire will be administered three times: Time 0 (pre) and Time 2 (after two months)

  • Confidence in decision making

    The questionnaire will be administered in two time-points of the study, Time 0 (pre) and Time 2 (after two months)

  • Patients engagement while learning

    on Time 2, namely about two weeks to four weeks after recruitment

Study Arms (2)

Educational intervention group

EXPERIMENTAL
Behavioral: Digital education

Control group

NO INTERVENTION

Interventions

Patients assigned to the experimental group will learn about symptom self-management in a digital learning environment.

Educational intervention group

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Gastrointestinal (GI) cancer patients
  • Chemotherapy session within a specific round of treatment, with eligible treatments including FOLFOX, FOLFIRINOX, and FLOT.
  • Hebrew speakers.

You may not qualify if:

  • Impaired or degraded cognitive capabilities that may hinder effective learning.
  • Individuals who discontinue their treatments due to terminal advancement of their disease or death.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ichilov Hospital

Tel Aviv, 6423906, Israel

RECRUITING

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 17, 2023

First Posted

January 2, 2024

Study Start

October 1, 2022

Primary Completion

June 1, 2024

Study Completion

November 1, 2024

Last Updated

January 3, 2024

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will not share

upon request

Locations